Eli Lilly and CompanyLLYNYSE
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+16.8%
5Y CAGR+14.0%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+16.8%/yr
vs +9.1%/yr prior
5Y CAGR
+14.0%/yr
Consistent
Acceleration
+7.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.9x
Solid growth
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $10.56B | +25.5% |
| 2024 | $8.42B | +18.9% |
| 2023 | $7.08B | +6.8% |
| 2022 | $6.63B | -9.3% |
| 2021 | $7.31B | +33.4% |
| 2020 | $5.48B | +16.1% |
| 2019 | $4.72B | +0.8% |
| 2018 | $4.68B | +5.3% |
| 2017 | $4.45B | -22.1% |
| 2016 | $5.71B | - |